The Business Research Company’s report on the Tyrosine Kinase Inhibitors Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the tyrosine kinase inhibitors market’s growth in recent years?
The increasing prevalence of cancer is expected to propel the growth of the tyrosine kinase inhibitors market going forward. Cancer refers to a broad collection of illnesses that begin in any organ or tissue of the body, where abnormal cells grow out of control, cross their usual boundaries to infect nearby body parts, and spread to other organs. The tyrosine kinase inhibitors are used in targeted therapy to target and kill cancer cell types by blocking tyrosine kinases that aid in preventing the growth of cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased from 1,898,160 in 2021 to 1,958,310 in 2023, reflecting a growth of 3.16%. Therefore, the increasing prevalence of cancer is driving the growth of the tyrosine kinase inhibitors market.
Access Your Free Sample of the Global Tyrosine Kinase Inhibitors Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11957&type=smp
How does the future projection of the tyrosine kinase inhibitors market size compare to its historical growth?
The tyrosine kinase inhibitors market size has grown strongly in recent years. It will grow from $58.03 billion in 2024 to $63.25 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to the discovery of tyrosine kinases, understanding of cancer signaling pathways, approval of imatinib (Gleevec), the clinical success of early TKIs, and investment in research and development
The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $88.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing healthcare investments, biomarker-driven therapies, drug delivery innovations, precision medicine paradigm, pediatric oncology focus. Major trends in the forecast period include resistance mitigation strategies, development of CNS-penetrant tkis, non-oncology applications, liquid biopsies for monitoring, health economic considerations.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=11957&type=smp
Which key players are shaping the future of the tyrosine kinase inhibitors market?
Major companies operating in the tyrosine kinase inhibitors market include Pfizer Inc., Johnson And Johnson Private Limited., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd, Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Glenmark Pharmaceuticals Ltd, Blueprint Medicines Corporation, Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., ArQule Inc.
What trends will propel the growth and evolution of the tyrosine kinase inhibitors market?
Product innovations are a key trend gaining popularity in the tyrosine kinase inhibitor market. Major companies operating in the tyrosine kinase inhibitor market are adopting new technologies to sustain their position in the market. For instance, in February 2023, Xspray Pharma AB, a Swedish pharmaceutical company, signed an agreement with EVERSANA, a US-based life sciences service company to assist with the U.S. launch and commercialization of its first innovative cancer therapy, Dasynoc, designed for treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasynoc offers a new and distinct treatment option for CML and ALL patients within the $3.5 billion U.S. market for Tyrosine Kinase Inhibitors. It represents a significant advancement for CML patients, as retrospective registry data presented at ASH 2022 revealed a 5-year overall survival rate of 79% for those treated with both a tyrosine kinase inhibitor (TKI) and proton pump inhibitor (PPI) (such as omeprazole), compared to 94% for patients on TKI alone.
Which regions are expected to become dominant players in the tyrosine kinase inhibitors market?
North America was the largest region in the tyrosine kinase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tyrosine kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report
What are the emerging key segments in the tyrosine kinase inhibitors market, and how are they evolving?
The tyrosine kinase inhibitors market covered in this report is segmented –
1) By Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other Types
2) By Distribution Channel: Hospital Pharmacy, Independent Pharmacies, Online Pharmacies
3) By Application: Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications
Subsegments:
1) By BCR-ABL Tyrosine Kinase Inhibitor: Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib
2) By Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: Gefitinib, Erlotinib, Afatinib, Osimertinib, Dacomitinib
3) By Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Pazopanib, Axitinib, Regorafenib
4) By Other Types: Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors, RET Tyrosine Kinase Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Other Emerging Tyrosine Kinase Inhibitors
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11957
What defines the structure and scope of the tyrosine kinase inhibitors market?
Tyrosine kinase inhibitors (TKI) refer to a class of pharmaceuticals that block several ways protein kinases signal the transduction pathway’s function. It is used in targeted therapy to target and kill cancer cell types while sparing healthy cells.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
